GSK plc files 6-K

GSK plc has entered into an exclusive collaboration with Sino Biopharmaceutical's subsidiary, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ), to accelerate the launch of bepirovirsen, a potential first-in-class treatment for chronic hepatitis B in mainland China. The agreement involves CTTQ purchasing bepirovirsen from GSK under agreed supply terms for an initial term of 5.5 years.